xoqylyjibo.wordpress.com
Urigen appointed Michael Goldberg tothe board, but will leavse the chairman position open. Goldberg, 50, is a managing partnetr of investment firm and from 1990 to 2007 was chairmanm and CEOof . Urigen has four drugw in clinical development, including a Phase II treatmengt of painfulbladder syndrome. The 4-year-old company lost nearly $1.7 million in the nine months endecMarch 31, compared with $4.1 million in the same period of the previoux fiscal year. The 52-week range for Urigen’s stoc has been 19 cents to 2 It closed Thursday at7 cents. who had served on Urigen’s board sinc December 2005, was at the cente of controversy with the Kansas TechnologyEnterprise Corp.
, a state agenc y charged with promoting technology business in Kansas. During state budgef negotiations that centeredon Taylor’s compensationn for the fiscal year endingv June 30, which amounted to almost a thirds of KTEC’s $1.1 millio n payroll, according to the .
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment